Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications.
Proton pump inhibitors (PPIs) are potent blockers of gastric acid secretion, and are widely regarded as the agents of choice for the treatment of acid-peptic disorders. For patients with upper gastrointestinal symptoms of uncertain etiology, improvement with PPI therapy is considered prima facie evidence of a pathogenetic role for acid-peptic disease. In addition to anti-secretory effects, however, PPIs have been found to have anti-oxidant properties and direct effects on neutrophils, monocytes, endothelial, and epithelial cells that might prevent inflammation. Those anti-inflammatory effects of the PPIs might influence a variety of inflammatory disorders, both peptic and non-peptic, within and outside of the gastrointestinal tract. The purpose of this report is to review the mechanisms whereby PPIs might exert anti-inflammatory effects exclusive of gastric acid inhibition, to discuss the clinical implications of those effects, and to emphasize that a clinical response to PPIs should not be construed as proof for an underlying acid-peptic disorder.
Kedika
Ramalinga R
RR
VA North Texas Healthcare System, Dallas, TX, USA.
Souza
Rhonda F
RF
Spechler
Stuart Jon
SJ
D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D016207:Cytokines / Q000096:biosynthesis; D042783:Endothelial Cells / Q000187:drug effects / Q000378:metabolism; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism; D041981:Gastrointestinal Tract / Q000382:microbiology; D006801:Humans; D007249:Inflammation / Q000188:drug therapy* / Q000378:metabolism; D010437:Peptic Ulcer / Q000175:diagnosis / Q000188:drug therapy*; D054328:Proton Pump Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*
D000975:Antioxidants; D016207:Cytokines; D054328:Proton Pump Inhibitors